Literature DB >> 21611725

Is two better than one? Combining antiresorptive and anabolic osteoporosis medications.

Nicole C Wright1, Kenneth G Saag.   

Abstract

Entities:  

Year:  2011        PMID： 21611725     DOI： 10.1007/s11914-011-0057-0

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN： 1544-1873            Impact factor:   5.096


× No keyword cloud information.
  6 in total

1.  Daily and cyclic parathyroid hormone in women receiving alendronate.

Authors:  Felicia Cosman; Jeri Nieves; Marsha Zion; Lillian Woelfert; Marjorie Luckey; Robert Lindsay
Journal:  N Engl J Med       Date:  2005-08-11       Impact factor: 91.245

2.  Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.

Authors:  S A Foster; K A Foley; E S Meadows; J A Johnston; S S Wang; G M Pohl; S R Long
Journal:  Osteoporos Int       Date:  2010-08-27       Impact factor: 4.507

3.  PTH and interactions with bisphosphonates.

Authors:  J A Gasser; M Kneissel; J S Thomsen; L Mosekilde
Journal:  J Musculoskelet Neuronal Interact       Date:  2000-09       Impact factor: 2.041

4.  Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.

Authors:  Steven Boonen; Fernando Marin; Barbara Obermayer-Pietsch; Maria E Simões; Clare Barker; Emmett V Glass; Peyman Hadji; George Lyritis; Heide Oertel; Thomas Nickelsen; Eugene V McCloskey
Journal:  J Clin Endocrinol Metab       Date:  2007-12-26       Impact factor: 5.958

5.  Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.

Authors:  Paul D Miller; Pierre D Delmas; Robert Lindsay; Nelson B Watts; Marjorie Luckey; Jonathan Adachi; Kenneth Saag; Susan L Greenspan; Ego Seeman; Steven Boonen; Suzanne Meeves; Thomas F Lang; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2008-08-05       Impact factor: 5.958

6.  Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Authors:  Bruce Ettinger; Javier San Martin; Gerald Crans; Imre Pavo
Journal:  J Bone Miner Res       Date:  2004-01-19       Impact factor: 6.741
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.